These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3066339)

  • 1. Beneficial effect of PGI2 on circulating endothelial cells.
    Sinzinger H; Rauscha F; Fitscha P; Kaliman J
    Basic Res Cardiol; 1988; 83(6):597-601. PubMed ID: 3066339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Synergism of PGI2 and molsidomine in arterial occlusive disease].
    Sinzinger H
    Z Kardiol; 1991; 80 Suppl 5():51-3. PubMed ID: 1776336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged infusion of prostacyclin in patients with advanced stages of peripheral vascular disease: a placebo-controlled cross-over study.
    Hossmann V; Auel H; Rücker W; Schrör K
    Klin Wochenschr; 1984 Dec; 62(23):1108-14. PubMed ID: 6394890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of optimal infusion regimens for epoprostenol using radio labelled platelet uptake over atherosclerotic lesions in man.
    Sinzinger H; Fitscha P; Kaliman J; Silberbauer K; O'Grady J
    Br J Clin Pharmacol; 1987 Nov; 24(5):607-13. PubMed ID: 3325091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet resistance to prostacyclin. Enhancement of the antiaggregatory effect of prostacyclin by pentoxifylline.
    Manrique RV; Manrique V
    Angiology; 1987 Feb; 38(2 Pt 1):101-8. PubMed ID: 3030162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Endothelial factors and thrombocyte function].
    Schrör K
    Z Kardiol; 1991; 80 Suppl 5():3-6. PubMed ID: 1776333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacologic concepts for clinical use of prostaglandin E1].
    Schrör K
    Vasa Suppl; 1991; 33():335-6. PubMed ID: 1788746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of clinical prostacyclin infusions in advanced arterial disease on platelet function and plasma 6-keto PGF1 alpha levels.
    Machin SJ; Chamone DA; Defreyn G; Vermylen J
    Br J Haematol; 1981 Mar; 47(3):413-22. PubMed ID: 7006673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The platelet rebound phenomenon during PGI2-infusion occurs at the receptor level.
    Steurer G; Fitscha P; Sinzinger H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):435-8. PubMed ID: 2465947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructible peripheral arterial occlusive disease.
    Cronenwett JL; Zelenock GB; Whitehouse WM; Lindenauer SM; Graham LM; Stanley JC
    Surgery; 1986 Aug; 100(2):369-75. PubMed ID: 3526609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation.
    Gryglewski RJ; Chłopicki S; Uracz W; Marcinkiewicz E
    Med Sci Monit; 2001; 7(1):1-16. PubMed ID: 11208485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure to demonstrate beneficial effect of prostacyclin (PGI2) infusion on red blood cell deformability in patients with peripheral vascular disease: a possible role of the leukocytes.
    Parise P; Berrettini M; Grasselli S; de Cunto M; Nenci GG
    Angiology; 1992 Apr; 43(4):320-7. PubMed ID: 1558317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet hyperactivity in acute myocardial infarction in man--effects of prostacyclin.
    Mueller HS; Rao PS; Greenberg MA; Buttrick PM; Sussman II; Levite HA; Grose RM; Perez-Davila V; Strain JE; Spaet TH
    Herz; 1986 Apr; 11(2):116-26. PubMed ID: 2939012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic and transcardiac platelet activity in acute myocardial infarction in man: resistance to prostacyclin.
    Mueller HS; Rao PS; Greenberg MA; Buttrick PM; Sussman II; Levite HA; Grose RM; Perez-Davila V; Strain JE; Spaet TH
    Circulation; 1985 Dec; 72(6):1336-45. PubMed ID: 2933181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exogenous prostacyclin decreases vasoconstriction but not platelet thrombus deposition after arterial injury.
    Lam JY; Chesebro JH; Badimon L; Fuster V
    J Am Coll Cardiol; 1993 Feb; 21(2):488-92. PubMed ID: 8426015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with L-arginine is likely to stimulate generation of nitric oxide in patients with peripheral arterial obstructive disease.
    Gryglewski RJ; Grodzińska L; Kostka-Trabka E; Korbut R; Bieroón K; Goszcz A; Sławiński M
    Wien Klin Wochenschr; 1996; 108(4):111-6. PubMed ID: 8867484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased platelet activity after termination of prostacyclin infusion into man.
    Dembinska-Kiec A; Zmuda A; Grodzinska L; Bieron K; Basista M; Kedzior A; Kostka-Trabka E; Telesz E; Zelazny T
    Prostaglandins; 1981 May; 21(5):827-32. PubMed ID: 6803307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous prostacyclin (PGI2) infusion to 108 patients with ischaemic peripheral vascular disease: phase II-open study.
    Virgolini I; Fitscha P; Weiss K; Linet OI; O'Grady J; Sinzinger H
    Prostaglandins; 1991 Jul; 42(1):9-14. PubMed ID: 1771241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro studies of thromboresistance: the role of prostacyclin (PGI2) in platelet adhesion to cultured normal and virally transformed human vascular endothelial cells.
    Curwen KD; Gimbrone MA; Handin RI
    Lab Invest; 1980 Mar; 42(3):366-74. PubMed ID: 6244462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of intravenous infusion of prostacyclin (PGI2) or prostaglandin E1 (PGE1) in augmentation of skin flap blood flow and viability in the pig.
    Forrest CR; Pang CY; Zhong AG; Kreidstein ML
    Prostaglandins; 1991 Jun; 41(6):537-58. PubMed ID: 2052739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.